Spyridon Theofilopoulos
Co-founder of CholesteniX, Associate Professor of Medicine at Swansea University
Medicine / Biotechnology
Spyridon Theofilopoulos is a member of the Onassis Foundation Scholars' Association since 2009. His research work has led to several patents in Europe and the United States. He is a co-founder of CholesteniX company, which specializes in the development of specific cholesterol metabolites for the treatment of Parkinson's disease and the treatment of motor neuron disease.He has studied Biochemistry and completed his PhD in Developmental Neurobiology, both at Imperial College London. Subsequently, he worked as a postdoctoral researcher at the Institute of Biomedical Sciences of the Academy of Athens and as a Lecturer at the Medical School of the University of Thessaly. He was then a Forskare (Senior Researcher / Assistant Professor) for several years at the Department of Medical Biochemistry and Biophysics of the Karolinska Institute in Stockholm. Since 2017, he has been elected Associate Professor at the Medical School of Swansea University in the United Kingdom.
His research papers have been published in well-known scientific journals, such as “Nature Chemical Biology” (Theofilopoulos et al., 2013), “Journal of Clinical Investigation” (Theofilopoulos *, Griffiths * et al., 2014), “Journal of Biological Chemistry” (Theofilopoulos et al., 2019), “Cell Stem Cell” (Sacchetti et al., 2009) and several others.